Hein GE |
[Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. |
2001 |
Z Rheumatol |
pmid:11383046
|
Morony S et al. |
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. |
2001 |
Cancer Res. |
pmid:11389072
|
Abu-Amer Y |
IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. |
2001 |
J. Clin. Invest. |
pmid:11390419
|
Kon T et al. |
Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. |
2001 |
J. Bone Miner. Res. |
pmid:11393777
|
Fazzalari NL et al. |
The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. |
2001 |
J. Bone Miner. Res. |
pmid:11393778
|
Kim KJ et al. |
Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. |
2001 |
J. Biomed. Mater. Res. |
pmid:11410897
|
Haynes DR et al. |
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. |
2001 |
Rheumatology (Oxford) |
pmid:11426018
|
Szulc P et al. |
Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. |
2001 |
J. Clin. Endocrinol. Metab. |
pmid:11443182
|
Sakiyama H et al. |
Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. |
2001 |
J. Bone Miner. Metab. |
pmid:11448014
|
Choi Y et al. |
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. |
2001 |
Eur. J. Immunol. |
pmid:11449372
|